Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Neuf: real-world data on blinatumomab for ALL

Sabina Chiaretti • 9 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab
Neuf

Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, discusses results in the real-world setting for adult acute lymphoblastic leukemia (ALL) patients treated with blinatumomab in the Neuf study. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Sabina Chiaretti

1:32
The feasibility of TKI treatment discontinuation in patients with Ph+ ALL
Sabina Chiaretti • 10 Dec 2023
1:17
Retrospective real-world study evaluating compassionate use of ponatinib in R/R Ph-like ALL
Sabina Chiaretti • 10 Dec 2023
1:59
Final analysis of the GIMEMA LAL2116 (D-ALBA) trial: dasatinib + blinatumomab in Ph+ B-ALL
Sabina Chiaretti • 10 Dec 2023
1:05
Comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed Ph+ B-ALL
Sabina Chiaretti • 10 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals